KAKEN PHARMA, Last Fiscal Year Ordinary Profit Revised Downward by 1%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Tue Apr 8, 2025 3:30 pm JST Revision

4521 KAKEN PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

KAKEN PHARMACEUTICAL CO.,LTD. <4521> [TSE Prime] announced a performance revision after the market closed on April 8th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 has decreased 0.9%, from the previous forecast of 21.2 billion yen to 21 billion yen (compared to 9.95 billion yen in the previous period), leading to a reduction in the profit growth rate from 2.1 times to 2.1 times.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated ordinary profit has decreased 14.5%, from the previous forecast of 1.37 billion yen to 1.17 billion yen (compared to 4.22 billion yen in the same period of the previous year), leading to an increase in the profit decline rate from 67.4% to 72.2%.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	37,128	1,221	1,377	-86	-2.2	75	Nov 8, 2024	J-GAAP
Oct - Mar, 2024 New	42,628	1,221	1,177	-286	-7.5	75	Apr 8, 2025	J-GAAP
Revision Rate	+14.8%	0.0%	-14.5%	-232.6%	-241.7%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	88,500	20,800	21,200	14,200	359.9	190	Aug 7, 2024	J-GAAP
Mar, 2025 New	94,000	20,800	21,000	14,000	364.6	190	Apr 8, 2025	J-GAAP
Revision Rate	+6.2%	0.0%	-0.9%	-1.4%	+1.3%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	35,873	4,001	4,229	3,957	104.9	75	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	42,628	1,221	1,177	-286	-7.5	75	Apr 8, 2025	J-GAAP
YoY	+18.8%	-69.5%	-72.2%	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	72,984	7,998	8,727	5,440	144.8	150	May 10, 2023	J-GAAP
Mar, 2024	72,044	9,513	9,951	8,025	212.7	150	May 14, 2024	J-GAAP
Mar, 2025 Guidance	94,000	20,800	21,000	14,000	364.6	190	Apr 8, 2025	J-GAAP
YoY	+30.5%	+118.6%	+111.0%	+74.5%	+71.4%